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Tcells may be activated by the antigen-specific T cellreceptor (TCR)-CD3 com-
plex interactingeither with foreign antigen in associationwith self-major histocom-
patibility complex (MHC) proteins or by foreign MHC proteins. T cells may also
be activated by the cell surface receptor CD2 (T11, LFA-2, the T cell erythrocyte
receptor), a molecule ofMr 50,000 expressed on all human thymocytes and T cells.
Pairs ofmAbsdirected against different epitopes onCD2 will stimulate T cells(1-3).
While both the antigen-specific TCR and the CD2 pathways of T cell activation
may be triggered independently, several lines ofevidence suggest that they are func-
tionally interrelated. Incubation ofresting T cells with a nonstimulatory anti-CD3
mAb in the presence of an anti-CD2 mAb directed against a specific epitope (9-1
mAb) induces T cell stimulation (3). Modulation ofthe TCRCD3 complex by in-
cubationwithananti-CD3 mAb prevents subsequentactivation by stimulatory pairs
ofanti-CD2 mAb (1, 2, 4-6). WhetherCD3 expressionis required forCD2-dependent
activation or whether CD3 modulation induces a stateofrefractories to subsequent
stimulation is not clear. Some (7), but not all (6), CD3-deficient mutant T cell lines
may be stimulated by pairs ofanti-CD2 mAb. On theotherhand, while modulation
ofsurface CD2 expression does not inhibit anti-CD3-induced calcium mobilization
(5), incubation of T cells with certain anti-CD2 mAb inhibits T cell stimulation
through the TCRCD3 complex (8-11), suggesting that CD2 may regulate T cell
responses.
A natural ligand for CD2 has been found to be lymphocyte function-associated
antigen 3 (LFA-3),' a widely distributed cell surface glycoprotein of Mr
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55,000-70,000. CD2 on the T cell participates in antigen-independent adhesion or
conjugate formation by binding to LFA-3 on the stimulator or target cell (12-15).
In addition to T cell adhesion, the CD2/LFA-3 interaction plays a role in T cell acti-
vation (16-18). Incubation of restingT cellswith sheep erythrocytes, whichbear an
LFA-3 homologue, in the presence of one anti-CD2 mAb induces human T cell
proliferation (16). Murine L cells transfected with and expressing human LFA-3 to-
gether with an anti-CD3 mAb or with suboptimal concentrations of phytohemag-
glutinin stimulate proliferation of human peripheral blood T cells (17).
To investigate the interaction of the CD2 activation pathway with the antigen-
specific TCR pathway, we have expressed a cDNA encoding the human CD2 mole-
cule in a murine T cell hybridoma that responds to HLA-DR antigens. We have
previously shown that this hybridoma produces IL-2 upon stimulation with pairs
of anti-CD2 mAb, such as 9.6 and 9-1 mAb, or with 9-1 mAb in the presence of
murine Lcells expressing human LFA-3 (18), demonstrating that the CD2 pathway
of activation is functional. CD2 expression markedly enhances IL-2 production in
response to LFA-3+ antigen-bearing stimulator cells, and this stimulation is in-
hibited by anti-CD2 and anti-LFA-3 mAb.
To further define the role of LFA-3 in antigen-dependent T cell activation, we
have studied the ability of the purified ligands of CD2 and the TCR to stimulate
the hybridoma. The HLA-DR-specific murine T cell hybridoma expressing CD2
produced IL-2 after stimulation with liposomes containing purified LFA-3 and HLA-
DR, the physiological ligands for CD2 and the TCR, respectively, suggesting that
complementaryinteractions betweenthe TCRCD3 complex and the CD2 pathway
may regulate lymphocyte activation. We have also constructed a cytoplasmic dele-
tion mutant of CD2, CD2AB, to examine the role of the CD2/LFA-3 interaction.
The behavior ofhybridomas expressing CD2AB allow a cleardistinction to be made
between the roles of adhesion and that of activation for the CD2/LFA-3 interaction.
Deletion ofthe cytoplasmic domain ofCD2 did not alterbindingof LFA-3 but elim-
inated the ability of CD2 to increase the response of the hybridoma to liposomes
containing both HLA-DR and LFA-3. These results suggest that the CD2/LFA-3
interaction not only plays arole in cell-celladhesion but provides a stimulatorysignal
for T cell activation.
Materials and Methods
Cell Culture.
￿
Cell lines were grown in DMEM (M . A. Bioproducts, Bethesda, MD) sup-
plementedwith 10% heat-inactivated FCS (Hazelton Research Products, Denver, PA), peni-
cillin 100 U/ml (Gibco Laboratories, Grand Island, New York), streptomycin 100ug/ml(Gibco
Laboratories), 10 mM Hepes (M . A. Bioproducts), and 2 mM glutamine (Gibco Laborato-
ries). All assays for IL-2 were performed in RPMI-1640 (M. A. Bioproducts) supplemented
as above and including 50 pM 2-ME (Eastman Organic Chemicals, Rochester, NY).
Monoclonal Antibodies.
￿
Antibodies against LFA-3 (TS2/9) and CD2 (TS2/18) have been
previously described (19), and were used as ascites fluid or purified antibody. Additional anti-
CD2 mAb were obtained through the Third International Workshop on Leukocyte Typing
(20). F23.1, murine IgG, specific for V08 variable region of the murine TCR (21); 100.30.3
rat IgG26, specific for murine H-2k' (22); and LB3.1, murine IgG1, specific for mono-
morphic determinants of HLA-DR (23), were also used.
Production of CD2- and CD2AB-expressing Cell Lines.
￿
The CD2-expressing T cell hybrid-
omas were constructed as previously described (18). CD2AB was constructed by cleavage of
a CD2 cDNA with Ban II, treatment of the end with T4 DNA polymerase followed by liga-BIERER ET AL.
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tion to 12-mer Nhe I linkers (stop codon linkers; New England Biolabs, Beverly, MA). Diges-
tion of the resulting plasmid with Hind III and Bam HI released an 800-bp fragment ; this
was then introduced into the retroviralvector MNCstuffer (A. Peterson, unpublished). This
deletion removes the COOH-terminal 100 amino acids of CD2 and replaces them with a serine.
CD2 and CD20B producer lines were constructed, and infections were done as described
(24). Briefly, the murine T cell hybridoma 155.16, produced by the fusion of the HATsensitive
thymoma BW5147 with spleen cells from C57BL/6 mice primed with the human EBV
transformed cell line JY (24), was infected with defective retroviruses that impart resistance
to G418 and either CD2 or CD2AB expression to the host cell . Neomycin-resistant cell lines
were screened for wild-type or mutant CD2 expression by indirect immunofluorescence.
Immunofluorescent Flow Cytometry.
￿
5 x 105 hybridoma cells were washed twice with PBS
containing 2% FCS and 0.02% sodium azide, and then incubated at 4°C in the dark for
30 min with saturating concentrations of mAb. Cells were washed as above and incubated
with 5 pl FITC-conjugated goat F(ab')2 anti-mouse IgG antibody (FITC-GAM) (Tago Inc.,
Burlingame, CA) at 4°C for 30 min. Cells were washed twice and incubated with 10 nM
propidium iodide (Sigma Chemical Co., St. Louis, MO) in PBS. 5-10 x 103 cells were ana-
lyzed on an Epic V (Coulter Electronics, Hialeah, FL) fluorescence-activated cell sorter, during
which dead cells were excluded by propidium iodide fluorescence.
Purification of LFA-3.
￿
The purification of LFA-3 by affinity chromatography has been
described (16). In brief, purified anti-LFA-3 mAb TS 2/9 was coupled to cyanogen biomide-acti-
vated Sepharose CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ) as described (16) to
prepare the anti-LEA-3 affinity columns. JY cells were solubilized with 2% Triton X-100 in
PBS and were filtered. LFA-3 was purified from the lysate using an anti-LFA-3 column, washed
with 0.5 ° Jo Triton X-100in PBS, and eluted as described (16). The eluted protein was homoge-
neous as shown by SDS-PAGE and retained serological activity as demonstrated by dot blot
analysis.
Preparation ofHLA-DR andLFA-3Liposomes.
￿
For preparation of HLA-DR, JY membranes
were solubilized with 4% Nonidet P-40 as described (26). The HLA-DR antigen was im-
munoaf$nity purified by passage of solubilized membranes through preclearing columns of
Sepharose CL-4B, normal rabbit serum coupled to Sepharose CL-4B, and protein A-Sepharose,
followed by an anti-HLA-DR column made by coupling the mAb LB3 .1 (23) to protein
A-Sepharose. The column was eluted with 50 mM glycine/0.1% sodium deoxycholate, pH
11 .5. The fractions were neutralized with 2 M glycine, pH 2, dialyzed and concentrated by
ultrafiltration. The purified, detergent-solubilized HLA-DR (40 pg), purified LEA-3 (20 Vg),
and purified HLA-DR (40 pg) with LFA-3 (20 pg) (DR + LFA-3) were each combined with
detergent-solubilized JY membrane lipids (800 pg) from a chloroform/methanol extraction.
Liposomes were formed by removal of the detergent by dialysis, as described previously (23) .
The resulting liposomes were pelleted by centrifugation at 175,000g for 1 h and resuspended
in Tris-buffered saline.
Stimulation of IL-2 Production by T Cell Hybridomas.
￿
5 x 104 T cell hybridomas were in-
cubated with irradiated (100 cGy from a cesium source) JY stimulator cells or liposomes as
indicated, with or without mAb, in 0.6 ml RPMI-1640 complete media in 48-well flat-bottom
plates (Costar, Cambridge, MA). Cells were incubated for 24 h at 37°C in 5% C02 in air.
Culture supernatants were harvested, frozen, thawed, titrated by serial twofold dilutions,
and assayed for the presence of IL-2 by their ability to support the proliferation of an IL-2
dependent murine T cell line, CTLL-20 (27). Proliferation was assessed by the incorporation
of [3H]thymidine in a 4-h pulse after a 20-h incubation. Results are expressed relative to
the [3H]thymidine incorporation of CTLL-20 cultured with a standard rat Con A superna-
tant, in which half-maximal incorporation is defined as 100 U IL-2/ml.
Results
TCellHybridomas Expressing CD2RespondtoAntigenStimulationandtoLiposomes Con-
tainingHLA-DR andLFA-3. A murine T cell hybridoma, 155.16, was produced by
the fusion of the murine AKR thymoma BW5147 with C57BL/6 spleen cells stimu-
lated with the human EBVtransformedjY cell line and screened for antigen-specific1148
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IL-2 production . The parent cell line 155 .16, which produced IL-2 in response to
stimulation with HLA-DR antigens (24), was infected with a defective retrovirus
that imparts resistance toG418 and surface expression of the humanCD2 molecule
as described (18) . We have previously demonstrated that murine T cell hybridomas
expressing CD2 responded to pairs of anti-CD2 mAb such as 9.6 plus 9-1 mAb,
or to the combination of 9-1 mAb and either sheep erythrocytes or murine L cells
expressing human LFA-3 (18) . This suggests that CD2 expressed by the murine hy-
bridomawas functional andthat LFA-3 may replace the signal provided by 9.6 mAb
binding.
Expression of the CD2 molecule in the murine hybridoma 155.16 markedly en-
hanced IL-2 production in comparison to theparent hybridoma in response to antigen-
specific stimulation with the HLA-DR' JY cell line (Fig. 1) . While there was clonal
variability in responsiveness, the CD2' hybridomas produced an average of 10-fold
(range 3-30-fold) more IL-2 than the parent cell line to the same number ofJY
stimulator cells (data not shown) . CD2' hybridomas that express equivalent levels
ofCD2 and the TCR, as assessed by indirect immunoflourescence, were compared
(data not shown) . In response toJY cell stimulation, 16.CD2-15 produced approxi-
mately 10-20-fold more IL-2, and 16.CD2-43 produced three- to sixfold more IL-2,
compared with the parent line . Stimulation of the CD2' hybridomas, but not the
parent, was inhibited by mAb directed against either CD2, expressed on the hy-
bridoma, or LFA-3, expressed on theJY stimulator cells, suggesting that theCD2/LFA-
3 interaction augmented the antigen-dependent response (Fig . 1) .
To define the role of LFA-3 in antigen-dependent T cell stimulation, we inves-
tigated whether purified LFA-3 andHLA-DR proteins incorporated into liposomes
would stimulate the CD2' murine T cell hybridomas. LFA-3 and HLA-DR an-
tigens were immunoaffinity purified from JY cells and the purified proteins were
incorporated into liposomes . Neither the parent nor the CD2' hybridomas pro-
duced IL-2 when liposomes containing only purified HLA-DR antigens were added
(Table I) . However, the CD2' hybridomas, 16.CD2-15 and 16.CD2-18, but not the
parent hybridoma, produced IL-2 in response to incubation with liposomes con-
taining both LFA-3 and HLA-DR antigens incorporated into the same liposome
(DR + LEA-3-liposomes) (Table I) . LFA-3 liposomes alone did not stimulate IL-2
production . Purified HLA-A2 incorporated into liposomes with HLA-DR antigens
FIGURE 1 .
￿
Inhibition of antigen-specific stimu-
lation of IL-2 production by the murine T cell
hybridoma 155.16 and the CD2' hybridomas
16.CD2-15 and 16.CD2-43 . 5 x 104hybridoma
cells were cultured with irradiated (100 cGyfrom
acesium source)JY stimulator cells, as described
in MaterialsandMethods, in the presence or ab-
sence ofmAb . The anti-CD2 mAb TS2/18 and
anti-LFA-3mAbTS2/9were used at a 1:1,200 di-
lution of ascites fluid. The anti-H2k k mAb
100.30.3 was used at a 10% final concentration
ofculture supernatant . All mAb concentrations
were saturating . Data are presented as units of
IL-2 activity per milliliter described in Materials
and Methods .BIERER ET AL .
￿
1149
TABLE I
HLA-DR + LFA-3-containing Liposomes Stimulate IL-2 Production by
CD2' Hybridomas
5 x 104 hybridoma cells were cultured for 24 h with irradiated JY cells (10 4 cells/
well), HLA-DR, LFA-3, or [DR + LFA-3]-containing liposomes (3 or 1 pl)
as indicated . Culture supernatants were assayed for the presence of IL-2 as
described in Materials and Methods . Liposomes were also prepared as described
in Materials and Methods .
did not stimulate IL-2 production (data not shown) . Thus, stimulation appeared
to require the presence of both HLA-DR, the ligand for the TCR, and LFA-3 .
Monoclonal antibody inhibition of the response of 16.CD2-15 to [DR + LFA-
3]-liposome stimulation was compared with that ofjY cell stimulation(Fig . 2) . Both
anti-CD2 (TS2/18) and anti-LFA-3 (TS2/9) mAb substantially inhibited IL-2 produc-
tion in response to both stimuli. Similarly, mAb directed against monomorphic de-
terminants ofHLA-DR (LB3 .1) inhibited both stimulations . However, mAbdirected
against murineMHC class I antigen H-2kk (100.30.3) did not inhibit IL-2 produc-
tion . These data demonstrated that stimulation of IL-2 production was dependent
upon expression ofCD2 on -the T cell, and upon the LFA-3 andHLA-DR antigens
expressed on the stimulator cell or in liposomes .
FIGURE 2 .
￿
Inhibition of antigen and [DR + LFA-3]-liposome stimulation ofIL-2 production .
5 x 104 CD2' hybridoma cells (16.CD2-15) were cultured with 10 5 irradiated (100 cGy from
a cesium source) JY stimulator cells (A), or 3 pl [DR + LFA-3]-liposomes (B), as described in
Materials and Methods, in the presence or absence of mAb, as indicated . The anti-CD2 mAb
TS2/18 and anti-LFA-3 mAb TS2/9 were used at a 1 :1,200 dilution of ascites fluid. The anti-
HLA-DR mAb LB3 .1 and anti-H-2kk mAb 100.30 .3 were used at a 5% final concentration of
culture supernatant . Data are presented as units of IL-2 activity per milliliter as described in
Materials and Methods . Note difference in scale of horizontal axis .
Stimulant 155.16
IL-2 production
16.CD2-15 16.CD2-18
U/ml
None <10 <10 <10
JY cells 165 1,660 445
HLA-DR liposomes <10 <10 <10
LFA-3 liposomes <10 <10 <10
[DR + LFA-3]-liposomes (3 ul) <10 1,910 510
[DR + LFA-3]-liposomes (1 ul) <10 1,480 2151150
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Expression and Function ofCD2AB Molecules in the Murine T Cell Hybridoma .
￿
The
CD2/LFA-3 interaction may participate in antigen-dependentT cell stimulation by
increasing adhesion of the stimulator cell to the T cell and/or by providing a signal
required forT cell activation . LFA-3 incorporated into [DR + LFA-3]-liposomes
may allow adhesion to CD2 on the T cell, promoting the interaction of the TCR
with HLA-DR antigens . To determine whetherthe CD2/LFA-3 interaction partici-
pates in cell-cell adhesion and provides an activation signal, we have constructed
a cytoplasmic deletion cDNA mutant ofCD2, CD2AB, in whichthe COON-terminal
100 amino acids of CD2 have been replaced with a serine (Fig . 3) . 155.16 was in-
fected with adefectiveretrovirus that imparts resistance toG418 and surfaceexpres-
sion ofCD2AB. G418-resistant cell lines were analyzed by indirect immunofluores-
cence forCD2AB expression . Eight cell lines that expressed the murine TCR and
mutant CD2AB molecules at levels equivalent to the wild-typeCD2+ hybridomas
were chosen for further study, an example ofwhich is shown in Fig. 4 . The expres-
sion of the murine TCR, assessed by indirect immunofluorescence using F23.1, an
mAb specific for the V08 region of the TCR, was equivalent on the parent hy-
bridoma, the CD2+ hybridoma 16.CD2-15, and the hybridoma expressing the de-
letion mutant 16.CD2AB-7 (Fig . 4) . Indirect immunofluorescence oftheCD2+ and
CD2AB' hybridomas using a panel ofanti-CD2 mAb was equivalent (Fig . 4 and
data not shown) . The expression of the LFA-1 molecule was equivalent on all cell
lines (data not shown) .
Eight hybridomas expressing the CD2AB molecule were analyzed . All eight
CD2AB' cell lines were able to produce equivalent amounts of IL-2 as the wild type
CD2' hybridomas upon stimulation with phorbol-12-myristate-13-acetate and the
calcium ionophore ionomycin (data not shown) . No CD2AB' hybridoma responded
to combinations of stimulatory pairs of anti-CD2 mAb, such as 9 .6 or 9-1 (Table
II and data not shown) . Four CD2AB' T cell hybridomas showed no enhanced re-
sponsiveness toJY stimulation, and four deletion mutants showed a slight enhance-
ment of IL-2 production (1 .5-2-fold) in comparison to the parent 155 .16 (Table II
and data not shown) . Of the eight CD2AB' hybridomas, the most responsive cell
line, 16.CD2AB-7, was analyzed forLFA-3 adhesion . 16.CD2AB-7 retains theability
to bind purified LFA-3 comparably to the wild type CD2' hybridoma . Scatchard
analysis of the binding of a soluble form of LFA-3 to the hybridomas expressing
CD2 and the CD2AB mutants showed that both had a Kd of 30 nM (A . Peterson,
manuscript in preparation) .
FIGURE 3 .
￿
Schematic diagram ofCD2 and CD2AB . Beneath the diagram of the CD2 mole-
cule, the amino acids of the cytoplasmic domain ofthe CD2 andCD2AB molecules are shown .
The COOH-terminal 100 amino acids ofCD2 are replaced by a serine in theCD2ABmolecule .
TM, transmembrane .m
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FIGURE 4.
￿
Expression of the murine TCR and human CD2 molecules by the murine T cell
hybridomas. Representative flow cytometric histograms are shown for the parent hybridoma 155.16,
the CD2' hybridoma 16.CD2-15, and the CD2AB' hybridoma 16.CD2AB-7. Hybridomas were
stained with saturating concentrations of mAb directed against the TCR (F23.1) and CD2 (9.6,
9.1) molecules, followed by incubation with FITC-GAM as described in Materials andMethods.
The negative controls were cells stained with FITC-GAM alone.
Since the hybridoma 16.CD2AB-7 was able to bind LFA-3 but unable to be stimu-
lated by pairs of anti-CD2 mAb, stimulation with [DR + LFA-3]-liposomes was
then assessed. Unlike the hybridomas expressing the wild type CD2 protein, the
CD2AB' did not respond to [DR + LFA-3]-liposomes (Table III), demonstrating
TABLE II
Stimulation of CD2' and CD2AB' Hybridomas
IL-2 production
155.16
16.CD2-15
Exp. 1
Stimulant
￿
155.16 16.CD2-15 16.CD2-18 16.CD2AB-7 16.CD2AB-14
U/ml
None
JY cells
9.6 + 9-1 mAb
MT110 + 9-1 mAb
Exp. 2
Stimulant
￿
155.16 16.CD2-15 16.CD2-43 16 .CD2AB-7 16 .CD2AB-8
1&CD2AB 7
5 x 104 hybridoma cells were cultured for 24 hwith irradiatedJY cells (104 cells/well), or with
mAb as indicated. 9.6, MTI10, MT910, and 9-1 mAb were used at a final concentration of
1 ug/ml. Incubation of the hydridomas with each anti-CD2 mAbalone did not stimulate IL-2
production (data not shown). Culture supernatants were assayed for the presence of IL-2 as
described in Materials and Methods.
k/1Ia i
Z~s
<10 <10 <10 <10 <10
410 >2,000 1,230 815 160
<10 825 240 <10 <10
<10 1,440 415 <10 <10
None <10 <10 <10 <10 <10
JY cells 100 >2,000 420 210 150
MT110 + 9-1 <10 905 300 <10 <10
MT910 + 9-1 <10 890 220 <10 <101152
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TABLE III
Stimulation by LFA-3 and HLA-DR Libosomes of Murine
T Cell Hybridoms
5 x 104 hybridoma cells were cultured for 24 h with liposomes (5 41) orJY cells
(105 cells/well) as indicated. Cultured supernatants were assayed for the presence
of IL-2 as described in Materials and Methods . HLA-DR, LFA-3, and [DR
+ LFA-3]-liposomes were also prepared as described in Materials and Methods.
that adhesion of LFA-3 to CD2 alone was insufficient for activation, and that the
cytoplasmic domain was required forLFA-3 stimulation through theCD2 molecule.
Discussion
In this report, we have demonstrated that murine T cell hybridomas expressing
the human CD2 molecule produce IL-2 in response to stimulation with purified
LFA-3 andHLA-DR incorporated into liposomes. LFA-3 mayparticipate in antigen-
dependentT cell stimulationviaCD2by promotingadhesion ofthe target or stimu-
lator cell to the T cell and/or by providing an activating signal to the T cell. In im-
mune interactions, adhesion preceeds antigenrecognition andT cell activation, and
these functions are therefore complementary. Stimulation of CD2+ hybridomas by
liposomes containing both LFA-3 and HLA-DR proteins would be consistent with
either role, since LFA-3 adheres to CD2 on the T cell and may allow the TCR to
interact with HLA-DR antigens more efficiently. Like antigen stimulation, the [DR
+ LFA-3]-liposome stimulation of the CD2+ hybridomas may be inhibited by mAb
directed against CD2, LFA-3, or HLA-DR.
The CD2AB+ hybridomas expressing a cytoplasmic deletion mutant of CD2 bind
LFA-3 comparably to wild-typeCD2, but are ineffective in allowing stimulation with
[DR + LFA-3]-liposomes. The Kd of CD2AB expressed in the hybridoma for LFA-
3 is the same as that of wild-type CD2. Furthermore, the CD2AB and wild-type
CD2 moleculestransfected into COS cellsboth promote adhesion to sheep erythro-
cytes, which express the sheep homologue of LFA-3 (A. Peterson, unpublished). If
adhesion alone were responsible for CD2-mediated stimulation of the hybridomas
response to antigen, then this mutant should be as effectiveas wild-typeCD2. How-
ever, no response is elicited by [DR + LFA-3]-liposomes. Thus, in this system, it
appears that a predominant effect of the CD2/LFA-3 interaction is to provide an
intracellular signal that synergizes with the signal provided by stimulation of the
TCRCD3 complex. This conclusion is supported by the response of the CD2AB+
hybridomas to incubation with intact JY cells, in which there was, at most, a slight
enhancementof IL-2 production compared to the parent hybridoma. This enhance-
ment could be attributed to the more limited role of adhesion.
Stimulant 155.16
IL-2 production
16.CD2-15 16.CD2-43 16.CD2AB-7
U/ml
None <10 <10 <10 <10
JY cells 260 7,395 1,210 540
DR liposomes <10 12 <10 <10
LFA-3 liposomes <10 <10 <10 <10
DR + LFA-3-liposomes <10 7,810 505 <10BIERER ET AL.
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We have previously shown that a hybridoma expressing a point mutant of CD2,
Q51L CD2, with a single amino acid substitution at position 51 of glutamine for
leucine, did not react with the 9.6 mAb, but had retained binding to and could be
stimulated to produce IL-2 to other anti-CD2 mAb with 9-1 mAb (18). The Q51L
CD2+ hybridomas did not respond to sheep erythrocytes nor murine L cells trans-
fected with and expressing human LFA-3 plus 9-1 mAb (18), demonstrating that
the Q51L CD2 molecule is unable to use LFA-3 for activation. Unlike the hybrid-
omas expressing the wild type CD2 molecule, the Q51L CD2+ hybridomas did not
exhibit enhanced IL-2 production in response to antigen-specificJY stimulation (18).
These findings support the conclusion that the inability ofQ51L CD2+ hybridomas
to demonstrate an enhanced response to JY cell stimulation is due to the inability
to bind LFA-3 expressed on the stimulator cell. The Q51L CD2+ hybridoma did
not respond to stimulation with [DR + LFA-3]-liposomes (datanot shown). These
data provide further evidence that the enhanced response observed with the wild
type CD2+ hybridoma is specific and depends upon the ability of LFA-3 to bind
to CD2.
We (18) and others (16) have shown that LFA-3 binding to CD2, in the presence
of one anti-CD2 mAb, induces antigen-independent T cell activation. Furthermore,
theCD2/LFA-3 interaction mayaffect Tcell stimulation viathe TCRCD3 pathway.
Resting human T cells may be stimulated to proliferate by one anti-CD3 mAb in
thepresence ofmurine Lcells expressing humanLFA-3 (17) or by an anti-CD2 mAb
(9-1) (3). Two signals are necessary to stimulate T cells by the CD2 pathway. T cell
function may be triggered by pairs ofanti-CD2 mAb (1-3), or by oneanti-CD2 mAb
in the presence of either an anti-CD3 mAb (3) or LFA-3 (16, 18). LEA-3 is widely
expressed on nucleated cells (9); however, the interaction of CD2 with LFA-3 alone
is insufficient for stimulation. Given the necessity for antigen to regulate the T cell
immune response in the periphery, the second signal for T cell stimulation may be
provided not through CD2, but through theTCR interacting with specific antigen.
The CD2/LFA-3 interaction may provide an accessory function to augment a weak
antigen-driven response. In this report, we have shown that Tcells may be activated
by purified LFA-3 binding to CD2 and the TCR interacting with its ligand, and
that these signals are synergistic forthe T cell. These findings extend previous data
on the biological role ofthe interaction of LEA-3 with CD2,-and oftheinterrelation-
ship of CD2 and the TCR. The signal provided by binding LFA-3 to CD2 alone
is insufficient for activation but may contribute to antigen-dependent T cell activa-
tion. A second signal, here provided by the TCR interacting with its ligand, is re-
quired for T cell activation. Whether a quaternary complex formed among CD2
and the TCRCD3 complex on the T cell, and LFA-3 and antigen/MHC on the
stimulator cell, allows for potentiation of these signals remains to be determined.
Summary
Tcells maybe activatedeither by the antigen-specific Tcell receptor (TCR)-CD3
complexor the cell surfacereceptor CD2. A naturalligand for CD2 has been found
to be lymphocyte function-associated antigen 3 (LEA-3), a widely distributed cell
surface glycoprotein. To investigate the interaction of these two pathways, we have
expressedthecDNA encoding thehuman CD2molecule in amurine T cell hybridoma
that produces IL-2 in response to HLA-DR antigens. Expression ofthe CD2 mole-1154
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cule markedly enhances IL-2 production in response to LFA-3+ antigen-bearing
stimulator cells, andthis stimulationis inhibited by anti-CD2 andanti-LFA-3 mAb.
To further define the role of LFA-3 in antigen-dependent T cell activation, we have
studied the ability of the purified ligands of CD2 and theTCR to stimulate thehy-
bridoma. Neither liposomes containing purified HLA-DR antigens nor liposomes
containing purified LFA-3 were able to stimulate the parent or the CD2+ hy-
bridoma. However, liposomes containing both purified LFA-3 and HLA-DR, the
physiological ligandsfor CD2 andthe TCR, respectively, stimulate IL-2 production
by the CD2+ but not the parent hybridoma, suggesting that complementary inter-
actions between the TCRCD3 complex and the CD2 pathway may regulate lym-
phocyte activation.
To determine whether the CD2/LFA-3 interaction participates in cell-cell adhe-
sion and provides an activation signal, we have constructed a cytoplasmic deletion
mutant of CD2, CD2AB, in which the COOH-terminal 100 amino acids of CD2
have been replaced with a serine. Hybridomas expressing the CD2AB molecule were
examined. Deletion of thecytoplasmic domain of CD2 did not alterbinding ofLFA-3
but eliminated the ability of CD2 to increase the response of the hybridoma to
liposomes containing both HLA-DR and LFA-3, demonstrating that adhesion of
LFA-3 to CD2 alonewas insufficient foractivation, andthat thecytoplasmicdomain
was required forLFA-3 stimulation through the CD2 molecule. Tcells may be acti-
vated by purified LFA-3 binding to CD2 and the TCR interacting with its ligand,
and these signals appear to be synergistic for the T cell. These results suggest that
the CD2/LFA-3 interaction not only plays a role in cell-cell adhesion but provides
a stimulatory signal for T cell activation.
Receivedfor publication 13 April 1988.
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